Video

Dr. Crane on the Impact of PARP Inhibitors in Ovarian Cancer

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.

In December 2014, olaparib (Lynparza) was approved by the FDA for use in patients with germline BRCA mutations who had 3 or more prior treatments. This has led to more PARP inhibitors being pushed through the pipeline, explains Crane, such as rucaparib (Rubraca), and niraparib (Zejula) for patients with recurrent disease.

Trials are being conducted in all-comers with platinum-sensitive disease, which may lead to further FDA approvals. Close to 1-year improvement in progression-free survival with a good quality of life has been seen with PARP inhibitors, says Crane.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Manali Kamdar, MD
Ibrahim Aldoss, MD
Kimberly Cannavale, MPH
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD